A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella
- PMID: 19561431
- PMCID: PMC2868313
- DOI: 10.1097/INF.0b013e3181998f06
A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella
Abstract
Herpes zoster, may be severe and recurrent in HIV-infected children. We determined the safety and immunogenicity of live attenuated varicella-zoster virus (VZV) vaccine in 46 HIV-infected children who had experienced varicella. There were no serious adverse events. Two years after vaccination 82% of subjects remained VZV-antibody positive and 60% had VZV-specific cell-mediated immunity. No child developed herpes zoster.
References
-
- Gershon A, Mervish N, LaRussa P, et al. Varicella-zoster virus infection in children with underlying HIV infection. J Infect Dis. 1997;176:1496–1500. - PubMed
-
- Son M, Shapiro E, LaRussa P, et al. Vaccination of children with perinatal HIV infection protects against varicella and zoster; Paper presented at: Pediatric Academic Societies Annual Meeting; May 3, 2008; Honolulu, HI.
-
- Wood SM, Shah SS, Steenhoff AP, et al. Primary varicella and herpes zoster among HIV-infected children from 1989 to 2006. Pediatrics. 2008;121:e150–e156. - PubMed
-
- Derryck A, LaRussa P, Steinberg S, et al. Varicella and zoster in children with human immunodeficiency virus infection. Ped Inf Dis J. 1998;17:931–933. - PubMed
-
- von Seidlein L, Gillette SG, Bryson Y, et al. Frequent recurrence and persistence of varicella-zoster virus infections in children infected with human immunodeficiency virus type 1. J Pediatr. 1996;128:52–57. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
